Polypeptides that bind an anti-tissue factor antibody and uses thereof
First Claim
1. An AATF antibody that specifically binds to a variable region of an anti-tissue factor antibody (ATF antibody) that specifically binds to an extracellular domain of a tissue factor.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies and polypeptides useful in blocking the binding of antibodies to anti-tissue factor, decreasing the activity of the anti-tissue factor antibodies and/or neutralizing the activity of an anti-tissue factor antibody. The present invention also relates to nucleic acids encoding the antibodies and polypeptides and compositions comprising the antibodies or polypeptides or nucleic acid molecules. The present invention provides methods of treating a hypercoagulable state or an inflammatory disease using the antibodies and polypeptides of this invention and other methods of using said antibodies and polypeptides.
-
Citations
47 Claims
- 1. An AATF antibody that specifically binds to a variable region of an anti-tissue factor antibody (ATF antibody) that specifically binds to an extracellular domain of a tissue factor.
-
17. A monoclonal antibody that binds essentially the same epitope as an antibody produced by the hybridoma cell line having the ATCC Deposit No. PTA-5066, deposited Mar. 20, 2003 as designation 6A6.3E11.2E12 in the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Va. 20110-2209, USA.
- 18. A monoclonal antibody having the biological characteristics of a 6A6 antibody produced by the hybridoma cell line having the ATCC Deposit No. PTA-5066, deposited Mar. 20, 2003 as designation 6A6.3E11.2E12 in the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Va. 20110-2209, USA.
-
24. An AATF polypeptide that binds to an ATF antibody comprising the sequences of
FIG. 13A andFIG. 13B , wherein the polypeptide comprises sequences:-
(a) residues 31-35 of FIG. 11B ;
(b) residues 50-65 of FIG. 11B ;
(c) residues 94-102 of FIG. 11B ;
(d) residues 26-35 of FIG. 12B ;
(e) residues 50-56 of FIG. 12B ; and
(f) residues 89-97 of FIG. 12B ;
ora variant of the AATF polypeptide that binds to an antibody comprising the sequences of FIG. 13A andFIG. 13B . - View Dependent Claims (25, 32, 36)
-
-
26. A AATF polypeptide comprising binding site described by the structural coordinates of amino acid residues T29, S30, Y32, W91, S93, W96 of a light chain according to Table 7 and amino acid residues Y27, H32, L50, H52, H53, N54, R94, E95, F97, R98, Y99, Y100A of a heavy chain according to Table 7.
-
27. A AATF polypeptide comprising a sequence starting at one of amino acid residues G31 to H32 and ending at one of amino acid residues Y100A to Y102 as set forth in
FIG. 11B .
-
28. A crystalline form of an antibody having the atomic coordinates recited in Table 8.
-
29. A crystalline form of a protein complex having the atomic coordinates recited in Table 8.
-
30. A crystalline form of a protein complex having unit cell parameters of a=78.9 Å
- , b=85.8 Å
, c=92.4 Å
, α
=77.5°
, β
=75.9° and
γ
=63.3°
.
- , b=85.8 Å
Specification